These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32430151)

  • 1. Breast conservation therapy confers survival and distant recurrence advantage over mastectomy for stage II Triple Negative Breast cancer.
    Macfie R; Aks C; Panwala K; Johnson N; Jennifer Garreau
    Am J Surg; 2021 Apr; 221(4):809-812. PubMed ID: 32430151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
    Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?
    Raghavan RK; Ibrahim S; Jagathnath Krishna KM; Mathew BS
    J Cancer Res Ther; 2019; 15(5):1031-1034. PubMed ID: 31603106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
    Parker CC; Ampil F; Burton G; Li BD; Chu QD
    Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer is not a contraindication for breast conservation.
    Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F
    Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.
    Zumsteg ZS; Morrow M; Arnold B; Zheng J; Zhang Z; Robson M; Traina T; McCormick B; Powell S; Ho AY
    Ann Surg Oncol; 2013 Oct; 20(11):3469-76. PubMed ID: 23686101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis.
    Li H; Chen Y; Wang X; Tang L; Guan X
    Clin Breast Cancer; 2019 Dec; 19(6):e669-e682. PubMed ID: 31375327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    Golshan M; Loibl S; Wong SM; Houber JB; O'Shaughnessy J; Rugo HS; Wolmark N; McKee MD; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
    JAMA Surg; 2020 Mar; 155(3):e195410. PubMed ID: 31913413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival.
    Kindts I; Buelens P; Laenen A; Van Limbergen E; Janssen H; Wildiers H; Weltens C
    Breast; 2017 Apr; 32():18-25. PubMed ID: 28012411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy.
    Bhatti AB; Khan AI; Siddiqui N; Muzaffar N; Syed AA; Shah MA; Jamshed A
    Asian Pac J Cancer Prev; 2014; 15(6):2577-81. PubMed ID: 24761867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
    Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
    Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer.
    Bellon JR; Chen YH; Rees R; Taghian AG; Wong JS; Punglia RS; Shiloh RY; Warren LEG; Krishnan MS; Phillips J; Pretz J; Jimenez R; Macausland S; Pashtan I; Andrews C; Isakoff SJ; Winer EP; Tolaney SM
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):45-52. PubMed ID: 33713742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis.
    Wang J; Xie X; Wang X; Tang J; Pan Q; Zhang Y; Di M
    Surg Oncol; 2013 Dec; 22(4):247-55. PubMed ID: 24144808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast-Conserving Therapy is Associated with Improved Survival Compared with Mastectomy for Early-Stage Breast Cancer: A Propensity Score Matched Comparison Using the National Cancer Database.
    Wrubel E; Natwick R; Wright GP
    Ann Surg Oncol; 2021 Feb; 28(2):914-919. PubMed ID: 32661849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer.
    Almahariq MF; Quinn TJ; Siddiqui Z; Jawad MS; Chen PY; Gustafson GS; Dilworth JT
    Radiother Oncol; 2020 Jan; 142():186-194. PubMed ID: 31615634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer.
    Parviz M; Cassel JB; Kaplan BJ; Karp SE; Neifeld JP; Penberthy LT; Bear HD
    J Surg Oncol; 2003 Oct; 84(2):57-62. PubMed ID: 14502777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term recurrence rate and survival in different aged patients with breast cancer undergoing breast conserving therapy].
    Wang LZ; Li JF; Wang TF; Xie YT; Fan ZQ; He YJ; Ouyang T
    Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):127-133. PubMed ID: 33378805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.